Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

0 avis

Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Archive ouverte

Edité par CCSD ; American College of Physicians -

Biannual rituximab infusions over 18 months effectively maintain remission after a “standard” remission induction regimen for patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV)

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Reducing the Initial Number of Rituximab Maintenance-Therapy Infusions for ANCA-associated Vasculitides: Randomized-Trial Post-Hoc Analysis

Archive ouverte | Charles, Pierre | CCSD

International audience. Abstract Objective The randomized, controlled MAINRITSAN2 trial was designed to compare the capacity of an individually tailored therapy [randomization day 0 (D0)], with reinfusion only when ...

Corrigendum to: Reducing the Initial Number of Rituximab Maintenance-Therapy Infusions for ANCA-associated Vasculitides: Randomized-Trial Post-Hoc Analysis

Archive ouverte | Charles, Pierre | CCSD

International audience

Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials

Archive ouverte | Delestre, Florence | CCSD

International audience. Objective To compare the long-term efficacy and safety of azathioprine (AZA), 18-month fixed-schedule rituximab (RTX), 18-month tailored RTX and 36-month RTX in preventing relapses in patient...

Chargement des enrichissements...